Cargando…

Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells

Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitriou, Pantelitsa, Li, Jin, Tornillo, Giusy, McCloy, Thomas, Barrow, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272004/
https://www.ncbi.nlm.nih.gov/pubmed/34267927
http://dx.doi.org/10.1002/gch2.202000123
_version_ 1783721124125736960
author Dimitriou, Pantelitsa
Li, Jin
Tornillo, Giusy
McCloy, Thomas
Barrow, David
author_facet Dimitriou, Pantelitsa
Li, Jin
Tornillo, Giusy
McCloy, Thomas
Barrow, David
author_sort Dimitriou, Pantelitsa
collection PubMed
description Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high‐throughput tool for reproducible, flexible, and automated production of droplet‐based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom‐up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated “droplet incubator” drug assay platform.
format Online
Article
Text
id pubmed-8272004
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82720042021-07-14 Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells Dimitriou, Pantelitsa Li, Jin Tornillo, Giusy McCloy, Thomas Barrow, David Glob Chall Reviews Anticancer drug development is a crucial step toward cancer treatment, that requires realistic predictions of malignant tissue development and sophisticated drug delivery. Tumors often acquire drug resistance and drug efficacy, hence cannot be accurately predicted in 2D tumor cell cultures. On the other hand, 3D cultures, including multicellular tumor spheroids (MCTSs), mimic the in vivo cellular arrangement and provide robust platforms for drug testing when grown in hydrogels with characteristics similar to the living body. Microparticles and liposomes are considered smart drug delivery vehicles, are able to target cancerous tissue, and can release entrapped drugs on demand. Microfluidics serve as a high‐throughput tool for reproducible, flexible, and automated production of droplet‐based microscale constructs, tailored to the desired final application. In this review, it is described how natural hydrogels in combination with droplet microfluidics can generate MCTSs, and the use of microfluidics to produce tumor targeting microparticles and liposomes. One of the highlights of the review documents the use of the bottom‐up construction methodologies of synthetic biology for the formation of artificial cellular assemblies, which may additionally incorporate both target cancer cells and prospective drug candidates, as an integrated “droplet incubator” drug assay platform. John Wiley and Sons Inc. 2021-05-07 /pmc/articles/PMC8272004/ /pubmed/34267927 http://dx.doi.org/10.1002/gch2.202000123 Text en © 2021 The Authors. Global Challenges published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Dimitriou, Pantelitsa
Li, Jin
Tornillo, Giusy
McCloy, Thomas
Barrow, David
Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title_full Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title_fullStr Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title_full_unstemmed Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title_short Droplet Microfluidics for Tumor Drug‐Related Studies and Programmable Artificial Cells
title_sort droplet microfluidics for tumor drug‐related studies and programmable artificial cells
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272004/
https://www.ncbi.nlm.nih.gov/pubmed/34267927
http://dx.doi.org/10.1002/gch2.202000123
work_keys_str_mv AT dimitrioupantelitsa dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells
AT lijin dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells
AT tornillogiusy dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells
AT mccloythomas dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells
AT barrowdavid dropletmicrofluidicsfortumordrugrelatedstudiesandprogrammableartificialcells